New drugs: where did we go wrong and what can we do better?
Authors:
Abstract
More than half of new drugs entering the German healthcare system have not been shown to add benefit. Beate Wieseler and colleagues argue that international drug development processes and policies are responsible and must be reformedKeywords
This publication has 29 references indexed in Scilit:
- Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort studyBMJ, 2015
- Methodological approach to determine minor, considerable, and major treatment effects in the early benefit assessment of new drugsBiometrical Journal, 2015
- From adaptive licensing to adaptive pathways: Delivering a flexible life‐span approach to bring new drugs to patientsClinical Pharmacology & Therapeutics, 2014
- Accelerated Access to Innovative Medicines for Patients in NeedClinical Pharmacology & Therapeutics, 2014
- Assessment of the therapeutic value of new medicines marketed in AustraliaJournal of Pharmaceutical Policy and Practice, 2013
- International comparison of assessments of pharmaceutical innovationHealth Policy, 2012
- Superior efficacy of new medicines?European Journal of Clinical Pharmacology, 2010
- An update on the first decade of the European centralized procedure: how many innovative drugs?British Journal of Clinical Pharmacology, 2006
- “Breakthrough” drugs and growth in expenditure on prescription drugs in CanadaBMJ, 2005
- Therapeutic Ratings and End‐of‐Phase II Conferences: Initiatives to Accelerate the Availability of Important New Drugs Kenneth I. Kaitin, PhDThe Journal of Clinical Pharmacology, 1991